VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
01.11.2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
01.11.2012
Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert
Weiter